Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Macrogenics (MGNX) EBT Margin (2016 - 2025)

Historic EBT Margin for Macrogenics (MGNX) over the last 14 years, with Q3 2025 value amounting to 23.09%.

  • Macrogenics' EBT Margin fell 277700.0% to 23.09% in Q3 2025 from the same period last year, while for Sep 2025 it was 51.61%, marking a year-over-year increase of 258000.0%. This contributed to the annual value of 44.03% for FY2024, which is 286100.0% down from last year.
  • Macrogenics' EBT Margin amounted to 23.09% in Q3 2025, which was down 277700.0% from 162.52% recorded in Q2 2025.
  • Over the past 5 years, Macrogenics' EBT Margin peaked at 50.86% during Q3 2024, and registered a low of 1686.79% during Q2 2024.
  • Over the past 5 years, Macrogenics' median EBT Margin value was 303.85% (recorded in 2021), while the average stood at 317.74%.
  • Per our database at Business Quant, Macrogenics' EBT Margin plummeted by -13386100bps in 2024 and then soared by 15242700bps in 2025.
  • Over the past 5 years, Macrogenics' EBT Margin (Quarter) stood at 411.65% in 2021, then skyrocketed by 104bps to 16.39% in 2022, then tumbled by -2908bps to 460.39% in 2023, then surged by 92bps to 36.19% in 2024, then surged by 164bps to 23.09% in 2025.
  • Its last three reported values are 23.09% in Q3 2025, 162.52% for Q2 2025, and 323.79% during Q1 2025.